Serre-Beinier Veronique: Key Insights from ELCC 2025
Serre-Beinier Veronique, Head of basic research lab at University Hospitals of Geneva, shared a post on LinkedIn:
“What groundbreaking advancements are shaping lung cancer treatment today?
Attending the European Lung Cancer Congress (ELCC) 2025 in Paris this week was truly enlightening. This premier event convened leading experts dedicated to advancing the fight against lung cancer.
Key highlights from the congress included:
- Innovations in early detection methods enhancing patient prognosis.
- Advancements in molecular characterization driving personalized therapies.
- Breakthroughs in immunotherapy offering new hope for patients.
- Integrative approaches emphasizing multidisciplinary collaboration. ESMO
World-leading experts also discussed breakthroughs in biomarkers, and liquid biopsy:
- Above RECIST: A new role for MRD and cfDNA in tumor assessment—can circulating biomarkers refine how we monitor treatment response? , Catherine Alix-Panabières, Atocha Romero, Heather Wakelee
- Biomarker testing: Sharing experiences among the countries—insights into the challenges and progress in making biomarker-driven treatment a global standard. Arnaud Bayle
A special session was dedicated to mesothelioma : - Update on the treatment of mesothelioma—new therapeutic strategies for this challenging malignancy. Scherpereel Arnaud, Isabelle Schmitt-Opitz
- Stratification of pleural mesothelioma patients for combined immunotherapy—Guillaume Tosato’s compelling presentation on tumor microenvironment markers in the IFCT-MAPS2 study.
How will these developments influence clinical practices?
What challenges do we face in implementing these innovations effectively?
Engaging with fellow oncology professionals at ELCC 2025 underscored the importance of collaboration in translating research into actionable treatments. The exchange of ideas and experiences is pivotal in our collective mission to combat lung cancer.”
Catherine Alix-Panabières shared this post, adding:
“Wonderful to have been involved in such a huge Congress in Paris ?
Liquid Biopsy will undoubtedly revolutionize cancer management in a soon future.”
More posts featuring ELCC25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023